Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

Weill Cornell -New York Presbyterian Hospital, New York

Montefiore Medical Center, New York

Charité Campus Virchow Klinikum, Berlin

A.O.U. San Martino, Genova

University of Pennsylvania, Philadelphia

Fondazione Centro San Raffaele del Monte Tabor, Milan

University of Virginia Medical Center, Charlottesville

South Carolina Oncology Associates, Columbia

CHU Morvan, Brest

Collaborative Research Group, LLC, Boynton Beach

CHU Bretonneau - Centre Kaplan, Tours

Sarah Cannon Research Institute, Nashville

Chattanooga Hem/Oncology Ass (SCRI), Chattanooga

Azienda Ospedaliera di Bologna - Policlinico S. Orsola Malpighi, Bologna

The Ohio State University Comprehensive Cancer Center, Columbus

Universitätsklinikum Essen, Essen

Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago

Washington University School of Medicine, St Louis

Centre Hospitalier de Lyon Sud, Pierre-Bénite

Charles A. Sammons Cancer Center, Dallas

Centre Henri Bequerel, Rouen

Klinikum der Universität München-Großhadern, München

Universitatsklinikum Ulm, Ulm

UCLA, Los Angeles

St. Jude Medical Center, Fullerton

Central Coast Medical Oncology, Santa Maria

Seattle Cancer Care Alliance, Seattle

Pacific Shores Medical Group, Long Beach

Stanford Cancer Center, Stanford

Winship Cancer Institute, Atlanta

John Theurer Cancer Center Hackensack University Medical Center, Hackensack

University of Medicine and Dentistry of NJ, New Brunswick

University of Wisconsin, Madison

"Università Sapienza", Rome

Małopolskie Centrum Medyczne, Krakow

Centrum Onkologii w Warszawie, Warsaw

St James's Institute of Oncology, Leeds

St Bartholemews Hospital, London

Sarah Cannon Institute, London

The Christie Hospital, Manchester

Southampton General Hospital, Southampton